Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orthofix MedicalFRA:OM2 +1.75%60 EV-to-EBIT is -13.57 as of Aug. 21, 2026. GuruFocus rates FRA:OM2 with a GF Score™ of 60/100 and a GF Value™ of €12.11 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 473 Medical Devices & Instruments companies, Orthofix Medical ranks worse than 211416.28% on this metric.
The historical rank and industry rank for Orthofix Medical's EV-to-EBIT or its related term are showing as below:
FRA:OM2'
s EV-to-EBIT Range Over the Past 10 Years
Min: -84.09 Med: -5.8 Max: 399.79
Current: -13.63
During the past 13 years, the highest EV-to-EBIT of Orthofix Medical was 399.79. The lowest was -84.09. And the median was -5.80.
FRA:OM2's EV-to-EBIT is ranked worse than 100% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 18.87
vs FRA:OM2: -13.63
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Orthofix Medical's Enterprise Value for the quarter that ended in Jun. 2026 was €449.6 Mil.
Orthofix Medical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-34.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orthofix Medical EV-to-EBIT Related Terms
Orthofix Medical EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Orthofix Medical's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Orthofix Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orthofix Medical EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Orthofix Medical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Orthofix Medical's EV-to-EBIT falls into.
Orthofix Medical's current Enterprise Value is €461.4 Mil.
Orthofix Medical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-34.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orthofix Medical (FRA:OM2) has a EV-to-EBIT of -13.57 as of Aug. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Orthofix Medical and its competitors. According to the industry distribution chart, Orthofix Medical ranks #999999 out of 473 companies in the Medical Devices & Instruments industry.
Is Orthofix Medical's EV-to-EBIT too high?
Orthofix Medical's current EV-to-EBIT is -13.57. Based on the distribution chart, Orthofix Medical ranks #999999 out of 473 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Orthofix Medical has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orthofix Medical's EV-to-EBIT compare to VMD and VREX?
According to the Medical Devices & Instruments industry distribution chart, Orthofix Medical ranks #999999 out of 473 companies for EV-to-EBIT. This places Orthofix Medical in the lower half of its industry. The industry median EV-to-EBIT is 18.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.87, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Orthofix Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orthofix Medical's current EV-to-EBIT is -13.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orthofix Medical stock overvalued right now?
Based on GuruFocus' analysis, Orthofix Medical (FRA:OM2) is currently considered Modestly Undervalued. The stock's GF Value™ is €12.11, compared to a current price of €8.70 — trading 28.2% below its estimated fair value. The current EV-to-EBIT is -13.57. Orthofix Medical's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Orthofix Medical (FRA:OM2), the current EV-to-EBIT is -13.57 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orthofix Medical (FRA:OM2) Overvalued in 2026?
Based on GuruFocus' analysis, Orthofix Medical stock appears to be undervalued.
The current stock price of €8.70 is trading 28.2% below its estimated GF Value™ of €12.11.
GuruFocus considers Orthofix Medical to be Modestly Undervalued.
Key valuation signals for FRA:OM2:
EV-to-EBIT: -13.57
GF Value™: €12.11 vs. price of €8.70 (28.2% below fair value)
No single metric tells the full story. See the FRA:OM2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
60GF Score
Get the complete analysis for FRA:OM2
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OM2 has been successfully added to your 
